Literature DB >> 15611402

Angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists.

Dionysios E Kyrmizakis1, Chariton E Papadakis, Antonios D Liolios, Alexandros D Karatzanis, Stylianos Malandrakis, Charalambos E Skoulakis, John G Bizakis, George A Velegrakis.   

Abstract

The use of angiotensin-converting enzyme inhibitors (ACEIs) has been implicated in many cases of angioedema, but, given the potential mechanism of this complication, it was not expected to be caused by angiotensin II receptor blockers (ARBs). However, in the past few years, scattered reports of angioedema associated with ARBs have appeared in the medical literature. We performed a retrospective chart review from January 1, 1998, through June 30, 2003, and a review of the literature. During this time, we managed head and neck angioedema induced by ACEIs (n = 27) and ARBs (n = 4) in 31 patients. All of them had significant mucosal swelling, and in some of them dyspnea and dysphagia coexisted. The most frequently involved areas were the oral tongue (13 cases), uvula and soft palate (5 cases), and larynx, mouth floor, and lips (3 cases each). Angioedema may be a more common complication of ACEI and/or ARB use than originally thought. This complication may occur after long-term use of these drugs. We advise that ARBs not be prescribed to patients with a history of angioedema, particularly that due to the use of ACEIs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15611402     DOI: 10.1001/archotol.130.12.1416

Source DB:  PubMed          Journal:  Arch Otolaryngol Head Neck Surg        ISSN: 0886-4470


  4 in total

1.  Severe migratory Angioedema due to ACE inhibitors use.

Authors:  G Peltekis; D Palaskas; M Samanidou; A Fragakis; K Alexopoulos; A Kotsani; I Vogiatzis; E Kyrmizakis
Journal:  Hippokratia       Date:  2009-04       Impact factor: 0.471

2.  Effectiveness, safety and cost of drug substitution in hypertension.

Authors:  Atholl Johnston; Panagiotis Stafylas; George S Stergiou
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 3.  Clinical Immunology Review Series: An approach to the patient with angio-oedema.

Authors:  S Grigoriadou; H J Longhurst
Journal:  Clin Exp Immunol       Date:  2009-03       Impact factor: 4.330

Review 4.  Emerging Novel Therapies for Heart Failure.

Authors:  Anthony M Szema; Sophia Dang; Jonathan C Li
Journal:  Clin Med Insights Cardiol       Date:  2015-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.